(S)-Methyl morpholine-2-carboxylate | 1314999-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (S)-Methyl morpholine-2-carboxylate
• 英文别名: methyl (2S)-morpholine-2-carboxylate
• CAS: 1314999-01-3
• 化学式: C₆H₁₁NO₃
• 分子量: 145.16
• InChiKey: RTITWBGWTASYEG-YFKPBYRVSA-N

物化性质

• 沸点：
  202.2±30.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLYL-SPIRO [2,3] HEXANE-CARBONITRILE COMME INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES, ET UTILISATIONS DE CEUX-CI
  申请人：MERCK SHARP & DOHME

  公开号：WO2019074810A1

  公开（公告）日：2019-04-18

  The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及Formula (I)的某些取代的反向吲唑化合物及其药学上可接受的盐，其中R1A、R1B、X、Y、RZ和R2如本文所定义，这些化合物是LRRK2激酶的强效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病和本文所述的其他疾病和疾病中有用。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗LRRK-2激酶参与的这类疾病中使用这些化合物和组合物。
• 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200123140A1

  公开（公告）日：2020-04-23

  Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

  公开了化学式A的4-嘧啶-5-基甲基吗啉及其药用盐，其中R1和R2如本文所定义。还公开了它们的制备方法、含有这些化合物的药物组合物，以及它们在治疗中的应用，特别是在与NR2B负变构调节性质相关的疾病的治疗或预防中的应用。
• 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200121691A1

  公开（公告）日：2020-04-23

  Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

  揭示了具有A式的4-吡嗪-2-甲基-吗啉及其药用盐，其中R1和R2如本文所定义。还揭示了它们的制备方法，含有这些化合物的药物组合物，以及它们在治疗中的应用，特别是在与NR2B负向变构调节性质相关的疾病的治疗或预防中。
• Zwitterionic tachykinin receptor antagonists
  申请人：——

  公开号：US20020042431A1

  公开（公告）日：2002-04-11

  The present invention is directed to certain novel compounds represented by structural formula I: 1 or a pharmaceutically acceptable salt thereof, wherein R 3 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 R 13 , Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.

  本发明涉及由结构式I：1所代表的某些新化合物或其药用可接受的盐，其中R3、R5、R6、R7、R8、R11、R12、R13、Q、W、X、Y和Z在此定义。该发明还涉及含有这些新化合物作为活性成分的药物配方，以及该新化合物及其配方在治疗某些疾病中的用途。本发明的化合物是催吐肽受体拮抗剂，可用于治疗包括抑郁症和焦虑症在内的精神障碍。
• 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200123141A1

  公开（公告）日：2020-04-23

  Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

  揭示了式A的4-吡啶甲基-吗啉和其药用可接受的盐，其中R1和R2在此处定义。还揭示了它们的制备过程，含有这些化合物的药物组合物，以及它们在治疗中的用途，特别是在与NR2B负性变构调节性质相关的疾病的治疗或预防中的用途。